Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

A Peptide Inhibitor for Treatment of Acute Lung Injury

Description:

Acute lung injury, peroxiredoxin 6, phospholipase A2

 

Inventors

Aron B. Fisher, Sheldon I. Feinstein, and Saikumari Y. Krishnaiah

 

Problem

Acute lung injury (ALI) is a common complication in critically ill patients.  It is characterized by acute severe hypoxia that may result in multi-organ failure.  There are limited treatment options for lung failure and ALI, with most providing only supportive care.

 

Solution

Previous studies have indicated that oxidative stress and inflammation play a critical role in the pathogenesis of ALI.  Peroxiredoxin 6 (Prdx6), which is widely expressed in lung tissue, may contribute to ALI by activation of NADPH oxidase leading to increased generation of reactive oxygen species (ROS). The increase in ROS can result in tissue oxidation and increased lung permeability. Dr. Aron Fisher’s lab identified a peptide that inhibits the phospholipase A2 (PLA2) activity of Prdx6, thereby reducing the generation of ROS. This work suggests that this novel peptide may have a therapeutic role in ALI.

 

Advantage

• Non-toxic inhibitor of the major cause of lung oxidative stress

 

Applications

• Prevention and treatment of ALI

 

Stage of Development

Studies completed in pulmonary microvascular endothelial cells

Studies ongoing in mouse model of ALI

 

Intellectual Property

Provisional Pending

 

Reference Media

Krishnaiah SY et al. Biochim Biophys Acta, 2016, 1864(4): 419-25

Desired partnerships

• License

Co-development

  

Docket #  16-7773


Patent Information:
For Information, Contact:
Viviane Martin
Director, PSOM Licensing Group
University of Pennsylvania
215-746-4275
martinv@upenn.edu
Inventors:
Aron Fisher
Saikumari Krishnaiah
Sheldon Feinstein
Keywords: